Cover Story

Pancreatic α cells secrete glucagon, which controls blood glucose levels. In patients with type 1 or type 2 diabetes, hyperglycemia is often associated with hyperglucagonemia. High levels of glucagon have been shown to contribute to diabetic hyperglycemia. Thus, suppressing glucagon secretion could be a novel strategy for treating diabetes. However, the mechanism underlying excessive glucagon secretion is not fully understood. Glucose uptake into α cells was previously thought to be controlled solely by the passive glucose transporter GLUT1; however, a recent report described the expression of sodium glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in α cells.

Suga et al. suggest that a novel mechanism regulates glucagon secretion through SGLT1 in α cells. Their findings may explain the distinct effects of selective SGLT2 inhibitors and mixed SGLT1/2 inhibitors on plasma glucagon levels in mice and might have implications for the classification and selection of SGLT2 inhibitors in the treatment of diabetes. Moreover, SGLT1 in α cells might contribute to the mechanism underlying hyperglucagonemia in diabetic patients.

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.

Randy J. Seeley, Henriette Frikke-Schmidt
Department of Surgery, University of Michigan, Ann Arbor, USA
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at
Conferences & Events
15 − 19
Cancer Metastasis
Florence, Italy
Media Coverage
Supported by